© 2000 American Heart Association, Inc.
Vascular Biology |
The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits
From the Departments of Cardiovascular Therapeutics (T.M.A.B., B.R.K., W.S.R., S.B.M., X.L., C.D., T.M.), Pharmacokinetics and Drug Metabolism (C.L.), and Chemistry (H.L.), Parke-Davis Pharmaceutical Research, Division of Warner-Lambert, 2800 Plymouth Rd, Ann Arbor, Mich.
Correspondence and reprint requests to Thomas M.A. Bocan, PhD, Department of Cardiovascular Therapeutics, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert, 2800 Plymouth Rd, Ann Arbor, MI 48105. E-mail thomas.bocant{at}wl.com
Abstract—Given the significance of cholesteryl ester (CE) accumulation in macrophage foam cell formation, we hypothesized that inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT) would produce a histologically stable lesion by limiting macrophage enrichment and thereby a source of matrix metalloproteinases (MMPs). Male New Zealand White rabbits were sequentially fed a cholesterol/fat diet for 9 weeks, a fat-only diet for 6 weeks, and 25 mg/kg avasimibe for 7 to 8 weeks. Avasimibe had no effect on plasma total cholesterol exposure. Plasma avasimibe maximal concentration and 24-hour area-under-the-curve levels were 178 ng/mL and 2525 ng · h/mL, respectively, after 7 weeks of treatment with 25 mg/kg avasimibe. The median inhibitory concentration against human monocyte-macrophage ACAT was 12 ng/mL when determined in the absence of albumin, and aortic arch avasimibe levels were 25 ng/g of tissue wet weight. Avasimibe reduced thoracic aortic and iliac-femoral CE content by 39%, the extent of thoracic aortic lesions by 41%, aortic arch cross-sectional lesions area by 35%, and monocyte-macrophage area by 27%. The reduction in monocyte-macrophage area reflected a change in cell number and not cell size. In the iliac-femoral artery, avasimibe decreased monocyte-macrophage content by 77% and reduced the macrophage-to-lesion ratio from 0.16 to 0.05. Within the aortic arch, the catalytic activity of latent and active MMP-9 was reduced by 65% and 33%, respectively; latent and active MMP-1 and MMP-3 activity measured collectively was decreased by 52% and 60%, respectively, and MMP-2 was unchanged. Aortic arch MMP-9, tissue inhibitor of matrix metalloproteinase (TIMP)-1, and TIMP-2 mRNA levels were reduced 29% to 39%, and MMP-2 mRNA levels increased. We conclude that the bioavailable ACAT inhibitor avasimibe can directly limit macrophage accumulation, resulting in the histological appearance of mainly fibromuscular lesions, and can potentially stabilize preestablished atherosclerotic lesions by reducing MMP expression within the lesion.
Key Words: atherosclerosis • ACAT • matrix metalloproteinases • macrophages • plaque rupture
This article has been cited by other articles:
 |
|
 |
|
  T.-Y. Chang, B.-L. Li, C. C. Y. Chang, and Y. Urano Acyl-coenzyme A:cholesterol acyltransferases Am J Physiol Endocrinol Metab, July 1, 2009; 297(1): E1 - E9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Kim, H. Moradi, J. Yuan, K. Norris, and N. D. Vaziri Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney Am J Physiol Renal Physiol, June 1, 2009; 296(6): F1297 - F1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Meuwese, E. de Groot, R. Duivenvoorden, M. D. Trip, L. Ose, F. J. Maritz, D. C. G. Basart, J. J. P. Kastelein, R. Habib, M. H. Davidson, et al. ACAT Inhibition and Progression of Carotid Atherosclerosis in Patients With Familial Hypercholesterolemia: The CAPTIVATE Randomized Trial JAMA, March 18, 2009; 301(11): 1131 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Fujiwara, N. Kiyota, M. Hori, S. Matsushita, Y. Iijima, K. Aoki, D. Shibata, M. Takeya, T. Ikeda, T. Nohara, et al. Esculeogenin A, a New Tomato Sapogenol, Ameliorates Hyperlipidemia and Atherosclerosis in ApoE-Deficient Mice by Inhibiting ACAT Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2400 - 2406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Nissen, E. M. Tuzcu, H. B. Brewer, I. Sipahi, S. J. Nicholls, P. Ganz, P. Schoenhagen, D. D. Waters, C. J. Pepine, T. D. Crowe, et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med., March 23, 2006; 354(12): 1253 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Kharbanda, S. Wallace, B. Walton, A. Donald, J. M. Cross, and J. Deanfield Systemic Acyl-CoA:Cholesterol Acyltransferase Inhibition Reduces Inflammation and Improves Vascular Function in Hypercholesterolemia Circulation, February 15, 2005; 111(6): 804 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. X. Rong, J. Kusunoki, P. Oelkers, S. L. Sturley, and E. A. Fisher Acyl-CoenzymeA (CoA):Cholesterol Acyltransferase Inhibition in Rat and Human Aortic Smooth Muscle Cells Is Nontoxic and Retards Foam Cell Formation Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 122 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Tardif, J. Gregoire, P. L. L'Allier, T. J. Anderson, O. Bertrand, F. Reeves, L. M. Title, F. Alfonso, E. Schampaert, A. Hassan, et al. Effects of the Acyl Coenzyme A:Cholesterol Acyltransferase Inhibitor Avasimibe on Human Atherosclerotic Lesions Circulation, November 23, 2004; 110(21): 3372 - 3377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. R Hiatt, E. Klepack, M. Nehler, J. G Regensteiner, J. Blue, J. Imus, and M. H Criqui The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease Vascular Medicine, November 1, 2004; 9(4): 271 - 277. [Abstract] [PDF]
|
|
|
|
|
|
N.D. Vaziri and K.H. Liang Acyl-Coenzyme A:Cholesterol Acyltransferase Inhibition Ameliorates Proteinuria, Hyperlipidemia, Lecithin-Cholesterol Acyltransferase, SRB-1, and Low-Denisty Lipoprotein Receptor Deficiencies in Nephrotic Syndrome Circulation, July 27, 2004; 110(4): 419 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Willner, B. Tow, K. K. Buhman, M. Wilson, D. A. Sanan, L. L. Rudel, and R. V. Farese Jr. Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice PNAS, February 4, 2003; 100(3): 1262 - 1267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Liang and N. D. Vaziri Upregulation of acyl-CoA:cholesterol acyltransferase in chronic renal failure Am J Physiol Endocrinol Metab, October 1, 2002; 283(4): E676 - E681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Major, L. Liang, X. Lu, W. Rosebury, and T. M.A. Bocan Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Is Induced Upon Monocyte Differentiation and Is Expressed in Human Atheroma Arterioscler. Thromb. Vasc. Biol., July 1, 2002; 22(7): 1200 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kusunoki, D. K. Hansoty, K. Aragane, J. T. Fallon, J. J. Badimon, and E. A. Fisher Acyl-CoA:Cholesterol Acyltransferase Inhibition Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice Circulation, May 29, 2001; 103(21): 2604 - 2609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. M. Delsing, E. H. Offerman, W. van Duyvenvoorde, H. van der Boom, E. C. M. de Wit, M. J. J. Gijbels, A. van der Laarse, J. W. Jukema, L. M. Havekes, and H. M. G. Princen Acyl-CoA:Cholesterol Acyltransferase Inhibitor Avasimibe Reduces Atherosclerosis in Addition to Its Cholesterol-Lowering Effect in ApoE*3-Leiden Mice Circulation, April 3, 2001; 103(13): 1778 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Buhman, H. C. Chen, and R. V. Farese Jr. The Enzymes of Neutral Lipid Synthesis J. Biol. Chem., October 26, 2001; 276(44): 40369 - 40372. [Full Text] [PDF]
|
|